5 Questions on Advanced Breast Cancer

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

The trial was terminated early due to no statistical significance observed between durvalumab and cetuximab for patients with head and neck squamous cell carcinoma.

Aditya Bardia, MD, MPH;Ritu Salani, MD;Scarlett Lin Gomez, PhD;Marwan G. Fakih, MD;Elizabeth Ren Zhang-Velten, MD, PhD;Frances Chow, MD;James B. Yu, MD, MHS, FASTRO

March 10th 2025

A Glimpse at Practice-Shifting Presentations at The 2025 SGO Annual Meeting

Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.

The 2025 SGO meeting will feature readouts of potentially impactful trial data in ovarian cancer, cervical cancer, and other gynecologic malignancies.

Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

The 2025 SGO meeting will feature readouts of potentially impactful trial data in ovarian cancer, cervical cancer, and other gynecologic malignancies.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Stephanie A. Berg, DO

March 7th 2025

Five-Year Impact of the COVID-19 Pandemic on the Oncology Community

A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.

ONCOLOGY Staff

Immunotherapy/Radiation Shows Responses in NSCLC Brain Metastases

Leading multidisciplinary oncology professionals look back at how the COVID-19 pandemic changed cancer care.

Retrospective data may offer actionable guidance for clinicians treating patients with non–small cell lung cancer and brain metastases.

March 12th 2025

Durvalumab Is Not Statistically Significant Vs Cetuximab in HNSCC

Retrospective data may offer actionable guidance for clinicians treating patients with non–small cell lung cancer and brain metastases.

Related Content

Ariana Pelosci

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

The trial was terminated early due to no statistical significance observed between durvalumab and cetuximab for patients with head and neck squamous cell carcinoma.

Aditya Bardia, MD, MPH;Ritu Salani, MD;Scarlett Lin Gomez, PhD;Marwan G. Fakih, MD;Elizabeth Ren Zhang-Velten, MD, PhD;Frances Chow, MD;James B. Yu, MD, MHS, FASTRO

March 10th 2025

A Glimpse at Practice-Shifting Presentations at The 2025 SGO Annual Meeting

Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.

Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

The 2025 SGO meeting will feature readouts of potentially impactful trial data in ovarian cancer, cervical cancer, and other gynecologic malignancies.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Stephanie A. Berg, DO

March 7th 2025

Five-Year Impact of the COVID-19 Pandemic on the Oncology Community

A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.

ONCOLOGY Staff

Immunotherapy/Radiation Shows Responses in NSCLC Brain Metastases

Leading multidisciplinary oncology professionals look back at how the COVID-19 pandemic changed cancer care.